EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC

Elena Elez, Scott Kopetz, Josep Tabernero, Tanios Bekaii-Saab, Julien Taieb, Takayuki Yoshino, Gulam Manji, Kathrine Fernandez, Antonello Abbattista, Xiaosong Zhang, Van K Morris

Future Oncology · 2024

DOI: 10.2217/fon-2022-1249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Elena Elez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron Hospital Campus & Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Antibodies, Monoclonal, Humanized, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, Funded by Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment of MSI-H/dMMR mCRC, and the BRAF inhibitor encorafenib, in combination with cetuximab, is approved for previously treated BRAF V600E-mutant mCRC. Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with BRAF V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated BRAF V600E-mutant, MSI-H/dMMR mCRC. Colorectal cancer (CRC) occurs when there is an abnormal growth of cells (known as a tumor) in the colon or rectum. Some people with CRC have changes in their tumor genes (known as gene mutations). A gene is a piece of DNA that tells the cell to make specific molecules, such as proteins. Mutations in a gene called BRAF can turn on signals that help the cancer cells grow. Gene mutations that impair DNA repair mechanisms can also make the cancer cells grow more quickly and allow the immune system to detect the cancer cells as being foreign to the body. Targeted therapy is a type of cancer treatment that turns off specific genes and proteins involved in cancer cell survival and growth. BRAF and EGFR inhibitors are targeted therapies that work well together in treating people with BRAF-mutant CRC. BRAF proteins can help cancer cells grow, and BRAF inhibitors block these proteins to prevent, slow, or stop the growth of the cancer cells. Immunotherapy is a type of cancer treatment that helps a person's immune system fight cancer. Immunotherapy is effective for treating CRC that has mutations in the DNA repair mechanisms. By combining targeted therapy and immunotherapy, patients may be able to live longer without their disease getting worse. In the SEAMARK study, we will use a treatment combination including a BRAF inhibitor (encorafenib), an EGFR inhibitor (cetuximab) and an immunotherapy (pembrolizumab) in patients with CRC who have a BRAF mutation and deficiencies in the DNA repair mechanism. Clinical Trial Registration: NCT05217446 (ClinicalTrials.gov), 2021-003715-26 (EudraCT).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsAntibodies, Monoclonal, HumanizedNeoplastic Syndromes, HereditarySulfonamidesBrain NeoplasmsCarbamatesHumansCetuximabProto-Oncogene Proteins B-rafMutationClinical Trials, Phase II as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

BRAF V600MSI-HcetuximabdMMRencorafenibimmunotherapymetastatic colorectal cancerpembrolizumabtargeted therapytriplet combination therapy

Substanzen

CetuximabpembrolizumabencorafenibProto-Oncogene Proteins B-rafAntibodies, Monoclonal, HumanizedSulfonamidesCarbamates

Autor:innen und Institutionen

  • Vall d'Hebron Hospital Campus & Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vall d'Hebron Hospital Campus & Vall d'Hebron Institute of Oncology, Universitat de Vic - Universitat Central de Catalunya, Barcelona, Spain.
  • Mayo Clinic, Phoenix, AZ, USA.
  • Georges Pompidou European Hospital, Université de Paris, Paris, France.
  • National Cancer Center Hospital East, Kashiwa, Japan.

Förderung

  • NCATS NIH HHS
  • Funded by Pfizer

Zitieren

APA

Elez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., Manji, G., Fernandez, K., Abbattista, A., Zhang, X., & Morris, V. K. (2024). SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. Future Oncology. https://doi.org/10.2217/fon-2022-1249

Vancouver

Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, et al. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. Future Oncology. 2024. doi:10.2217/fon-2022-1249

BibTeX
@article{Elez2024,
  author = {Elez, Elena and Kopetz, Scott and Tabernero, Josep and Bekaii-Saab, Tanios and Taieb, Julien and Yoshino, Takayuki and Manji, Gulam and Fernandez, Kathrine and Abbattista, Antonello and Zhang, Xiaosong and Morris, Van K},
  title = {SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2022-1249}
}
Kostenlos starten →